

box / A

Filing fee calculation:


- ☒ Please charge Deposit Account No. 19-0134 in the name of Novartis Corporation in the amount of \$1,136. An additional copy of this paper is enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.16 and §1.17 which may be required in connection with this application, or credit any overpayment, to Deposit Account No. 19-0134 in the name of Novartis Corporation.

Please address all correspondence to the address associated with Customer No. 001095, which is currently:

Thomas Hoxie  
Novartis Corporation  
Patent and Trademark Dept.  
564 Morris Avenue  
Summit, NJ 07901-1027

Please direct all telephone calls to the undersigned at the number given below, and all telefaxes to (908) 522-6955.

Respectfully submitted,



David E. Wildman  
Attorney for Applicants  
Reg. No. 40,226  
Tel. No. (908) 522-6946

Date: February 21, 2002

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EL 913014714 US  
Express Mail Label Number

February 21, 2002  
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

BRAZZELL ET AL.

APPLICATION NO: Not Yet Assigned

FILED: February 21, 2002

FOR: METHOD OF TREATING OCULAR NEOVASCULARIZATION


Assistant Commissioner for Patents  
Washington, D.C. 20231

SUBMISSION OF SEQUENCE LISTING  
INCLUDING STATEMENT OF VERIFICATION

Sir:

Applicants hereby provide a Computer Readable Form of the Sequence Listing as well as the Paper Copy thereof. The undersigned states that the Paper Copy and the Computer Readable Form, submitted in accordance with 37 CFR §1.821(c) and (e), respectively, are the same.

Respectfully submitted,



David E. Wildman  
Attorney for Applicants  
Reg. No. 40,226

Novartis Corporation  
Patent and Trademark Dept.  
564 Morris Avenue  
Summit, NJ 07901-1027  
(908) 522-6946  
Date: February 21, 2002

10080797 022403  
207220 2620800T